Lenalidomide Capsule
Product Images NDC 76282-696

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 76282-696). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

01-mar-2015-1 (01 Mar 2015 1)

The text describes a clinical study comparing the efficacy of Lenalidomide versus placebo in terms of progression-free survival. It provides data on hazard ratio, confidence intervals, and median survival times for each group. Additionally, it shows the number of subjects at risk and the percentage of progression-free survival events in each group. The study results suggest that Lenalidomide may be associated with improved progression-free survival compared to placebo.*

FDA Label Image

01-mar-2015-2 (01 Mar 2015 2)

This is a comparison of Lenalidomide versus placebo in terms of progression-free survival. The hazard ratio was 0.53 (95% CI: 0.44, 0.64) indicating a lower risk of progression with Lenalidomide. The median survival was also longer with Lenalidomide (46.3 months, 95% CI: 40.1, 56) compared to placebo (23.8 months, 95% CI: 21.0, 27.3). The number of subjects at risk and PFS events are also provided for both groups.*

FDA Label Image

03-mar-2014 (03 Mar 2014)

FDA Label Image

24-may-2013 (24 May 2013)

FDA Label Image

2point5mg (2point5mg)

FDA Label Image

Mm-study-1 (Mm Study 1)

This text provides information on the proportion of subjects at different points during a study, alongside statistics related to the survival analysis of the participants receiving Lenalidomide/Dex treatment for a specified duration of time. The hazard ratio (HR) and confidence interval (CI) values are indicated, along with the results of the log-rank test showing statistical significance. The number of subjects at various percentage levels (100%, 75%, 25%) is also presented.*

FDA Label Image

Mm-study-2 (Mm Study 2)

This data likely presents the results of a study comparing the proportion of subjects who experienced progression by a certain time point between two treatments, Lenalidomide/Dex and Placebo/Dex. The Hazard Ratio (HR) with 95% confidence interval is shown as 0.324 (0.240-0.438), indicating a significant difference between the two groups. Additionally, the Log Rank p-value is less than 0.001, further supporting the statistical significance of the findings. The chart also includes a visual representation of the time to progression in months for both groups.*

FDA Label Image

Augment-trail (Augment Trail)

FDA Label Image

Image Description (Lenali 1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.